Attenuation of electrical remodelling in chronic atrial fibrillation following oral treatment with verapamil

Europace

Volumn 1, Issue 4, 1999, Pages 234-241

  Meurling, C J ^a,c   Ingemansson, M P ^a   Roijer, A ^a   Carlson, J ^a   Lindholm, C J ^a   Smideberg, B ^a   Sornmo, L ^b   Stridh, M ^b   Olsson, S B ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND INSTITUTE OF TECHNOLOGY   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Arrhythmia; Atrial fibrillation; Ca channel; Remodelling; Verapamil

Indexed keywords

ANTIARRHYTHMIC AGENT; VERAPAMIL;

AGED; ARTICLE; BLOOD PRESSURE; CHRONIC DISEASE; DRUG EFFECT; FEMALE; HEART ATRIUM FIBRILLATION; HEART MUSCLE CONDUCTION SYSTEM; HEART RATE; HUMAN; MALE; MIDDLE AGED; PATHOPHYSIOLOGY;

AGED; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; BLOOD PRESSURE; CHRONIC DISEASE; FEMALE; HEART CONDUCTION SYSTEM; HEART RATE; HUMANS; MALE; MIDDLE AGED; VERAPAMIL;

EID: 0033206908     PISSN: 10995129     EISSN: None     Source Type: Journal    
DOI: 10.1053/eupc.1999.0055     Document Type: Article

References (46)

1. Lown B. Electrical reversion of cardiac arrhythmias. Br Heart J 1967; 29: 469-89.
2. van Gelder IC, Crijns HJ, van Gilst WH et al. Prediction of uneventful cardioversion and maintenance of sinus rhythm from Direct-Current electrical cardioversion of chronic atrial fibrillation and nutter. Am J Cardiol 1991; 68: 41-6.
3. Horowitz LN, Spielman SR, Greenspan AM et al. Use of amiodarone in the treatment of persistent and paroxysmal atrial fibrillation resistant to quinidine therapy. J Am Coll Cardiol 1985; 6: 1402-7.
4. Suttorp MJ, Kingma JH, Jessurun ER, Lie-a-huen L, van Hemel NM, Lie KI. The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or nutter to sinus rhythm. J Am Coll Cardiol 1990; 16: 1722-7.
5. Crijns HJ, van Wijk LM, van Gilst WH, Kingma JH, van Gelder IC, Lie KI. Acute conversion of atrial fibrillation to sinus rhythm: clinical efficacy of flecainide acetate. Comparison of two regimens. Eur Heart J 1988; 9: 634-8.
6. Morris JJ, Peter RH, McIntosh HD. Electrical conversion of atrial fibrillation. Ann Intern Med 1966; 65: 216-31.
7. Resnekov L, McDonald L. Appraisal of electroconversion in treatment of cardiac dysrhythmias. Br Heart J 1968; 30: 786-811.
8. Gold RL, Haffajee CI, Charos G, Sloan K, Baker S, Alpert JS. Amiodarone for refractory atrial fibrillation. Am J Cardiol 1986; 57: 124-7.
9. Crijns HJ, van Gelder IC, van Gilst WH, Hillege H, Gosselink AM, Lie KI. Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial nutter. Am J Cardiol 1991; 68: 335-41.
10. Hillestad L, Bjerkelund C, Dale J, Maltau J, Storstein O. Quinidine in maintenance of sinus rhythm after electroconversion of chronic atrial fibrillation. A controlled clinical study. British Heart Journal 1971; 33: 518-21.
11. Karlson BW, Torstensson I, Abjorn C, Jansson SO, Peterson LE. Disopyramide in the maintenance of sinus rhythm after electroconversion of atrial fibrillation. A placebo-controlled one-year follow-up study. Eur Heart J 1988; 9: 284-90.
12. Antman EM, Beamer AD, Cantillon C, McGowan N, Goldman L, Friedman PL. Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and nutter. J Am Coll Cardiol 1988; 12: 1005-11.
13. Crijns HJ, Gosselink ATM, Lie KI, for the PRODIS Study group. Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: A randomized, double-blind study. Cardiovasc Drugs Ther 1996; 10: 145-52.
14. Goette A, Honeycutt C, Langberg JJ. Electrical remodeling in atrial fibrillation. Time course and mechanism. Circulation 1996; 94: 2968-74.
15. Elvan A, Wylie K, Zipes DP. Pacing-induced chronic atrial fibrillation impairs sinus node function in dogs. Circulation 1996; 94: 2953-60.
16. Franz MR, Karasik PL, Li C, Moubarak J, Chavez M. Electrical remodeling of the human atrium: Similar effects in patients with chronic atrial fibrillation and atrial flutter. J Am Coll Cardiol 1997; 30: 1785-92.
17. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995; 92: 1954-68.
18. Tieleman RG, De Langen C, van Gelder IC et al. Verapamil reduces tachycardia-induced electrical remodelling of the atria. Circulation 1997; 95: 1945-53.
19. Daoud EG, Knight BP, Weiss R et al. Effect of verapamil and procainamide on atrial fibrillation-induced electrical remodeling in humans. Circulation 1997; 96: 1542-50.
20. Olsson SB, Cotoi S, Varnauskas E. Monophasic action potential and sinus rhythm stability after conversion of atrial fibrillation. Acta Med Scand 1971; 190: 381-7.
21. Brorson L, Olsson B. Right monophasic action potential in patients with paroxysmal supraventricular tachyarrhythmias. Acta Med Scand 1977; 201: 105-10.
22. Lammers WJEP, Allessie MA, Rensma PL, Schalij MJ. The use of fibrillation cycle length to determine spatial dispersion in electrophysiological properties and to characterize the underlying mechanism of fibrillation. N Trends Arrhyth 1986; 1: 109-12.
23. Misier AR, Opthof T, van Hernel NM et al. Increased dispersion of 'refractoriness' in patients with idiopathic paroxysmal atrial fibrillation. J Am Coll Cardiol 1992; 19: 1531-5.
24. Capucci A, Biffi M, Boriani G et al. Dynamic electrophysiological behaviour of human atria during paroxysmal atrial fibrillation. Circulation 1995; 92: 1193-202.
25. Kim KB, Rodefeld MD, Schuessler RB, Cox JL, Boineau JP. Relationship between local atrial fibrillation interval and refractory period in the isolated canine atrium. Circulation 1996; 94: 2961-7.
26. Holm M, Pehrson S, Ingemansson M et al. Noninvasive assessment of the atrial cycle length during atrial fibrillation in man. Introducing, validating and illustrating a new ECG method. Cardiovasc Res 1998; 38: 69-81.
27. Ingemansson MP, Holm M, Olsson SB. Autonomic modulation of the atrial cycle length by the head up tilt test: non-invasive evaluation in patients with chronic atrial fibrillation. Heart 1998; 80: 71-6.
28. Pehrson S, Holm M, Meurling C et al. Noninvasive assessment of magnitude and dispersion of atrial cycle length during chronic atrial fibrillation in man. Eur Heart J 1998; 19: 1836-44.
29. Stridh M, Sornmo L. Improved QRST cancellation techniques with application to atrial fibrillation analysis. In: Murray A, Swiryn S, eds. Computers in cardiology. Cleveland, Ohio: IEEE; 1998: 633-6.
30. Dollery C, ed. Therapeutic Drugs. Edinburgh: Churchill Livingstone, 1991.
31. Robertson RM, Robertson D. Drugs used for the treatment of myocardial ischemia. In: Hardman JD, Limbird LE, Molinoff PB, Ruddon RW, Goodman Gilman A, eds. Goodman & Gilman's The pharmacological basis of therapeutics. New York: McGraw-Hill, 1995: 766-74.
32. Singh BN, Nademanee K. Use of calcium antagonists for cardiac arrhythmias. Am J Cardiol 1987; 59: 153B-162B.
33. Rosen MR, Wit AL, Hoffman BF. Appraisal and reappraisal of cardiac therapy. Electrophysiology and pharmacology of cardiac arrhythmias. Cardiac effects of verapamil. Am Heart J 1975; 89: 665-73.
34. Boucher M, Dubray C, Duchene-Marullaz P. Effects of bepridil, diltiazem and verapamil on atrial refractoriness and heart rate in the conscious dog: comparison with quinidine. Gen Pharmacol 1991; 22: 581-7.
35. Lai W, Voon W, Yen H et al. Comparison of the electrophysiologic effects of oral sustained-release and intravenous verapamil in patients with paroxysmal supraventricular tachycardia. Am J Cardiol 1993; 71: 405-8.
36. Ramanna H, Elvan A, Hauer RN et al. Verapamil causes increase in dispersion and shortening of refractoriness in human chronic atrial fibrillation (Abstr). PACE 1998; 21: 51.
37. Duytschaever M, Mast F, Allessie M. Pro-fibrillatory effects of verapamil in a goat model of atrial fibrillation (Abstr). PACE 1998; 21: 199.
38. Zipes DP. Electrophysiological remodeling of the heart owing to rate. Circulation 1997; 95: 1745-8.
39. Tieleman RG, van Gelder IC, Crijns HJGM et al. Early recurrences of atrial fibrillation after electrical cardioversion: A result of fibrillation-induced electrical remodeling of the atria? J Am Coll Cardiol 1998; 31: 167-73.
40. Wijffels MCEF, Kirchhof CJHJ, Dorland R, Power J, Allessie MA. Electrical remodeling due to atrial fibrillation in chronically instrumented conscious goats. Circulation 1997; 96: 3710-20.
41. Bayer R, Kalusche D, Kaufmann R, Mannhold R. Inotropic and electrophysiological actions of verapamil and D600 in mammalian myocardium III. Effects of the optical isomers on transmembrane action potentials. Naunyn Schmiedebergs Arch Pharmacol 1975; 290: 81-97.
42. Singh BN, Vaughan Williams EM. A fourth class of antidysrhythmic action? Effect of verapamil on ouabain toxicity, on atrial and ventricular intracellular potentials, and on features on cardiac function. Cardiovasc Res 1972; 6: 109-19.
43. Cranefield PF, Aronson RS, Wit AL. Effect of verapamil on the normal action potential and on a calcium-dependent slow response of canine cardiac purkinje fibers. Circulation Res 1974; 34: 204-13.
44. Manning WJ, Silverman DI, Katz SE, Riley MF, Come PC, Doherty RM, Munson JT, Douglas PS. Impaired left atrial mechanical function after cardioversion: relation to the duration of atrial fibrillation. J Am Coll Cardiol 1994; 23: 1535-40.
45. Leistad E, Verburg G, Christensen G. Cytosolic calcium overload, not atrial ischemia, accounts for post-fibrillation atrial dysfunction (Abstr). Circulation 1994; 90 (Suppl I): 1-492.
46. Leistad E, Aksnes G, Verburg E, Christensen G. Atrial contractile dysfunction after short-term atrial fibrillation is reduced by verapamil but increased by BAY K8644. Circulation 1996; 93: 1747-54.